Novo Nordisk A/S (NYSE:NVO) Given Average Rating of “Hold” by Brokerages

Novo Nordisk A/S (NYSE:NVO) has been assigned a consensus rating of “Hold” from the thirteen brokerages that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $137.76.

A number of research analysts recently issued reports on the stock. Bank of America lifted their price target on shares of Novo Nordisk A/S from $355.00 to $400.00 and gave the company a “neutral” rating in a research report on Friday, September 13th. Pareto Securities cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Jefferies Financial Group downgraded shares of Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a research note on Friday, August 30th. Barclays raised Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, November 27th. Finally, UBS Group downgraded Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Monday, November 18th.

Shares of NYSE NVO traded up $0.65 during trading hours on Friday, hitting $57.17. The company’s stock had a trading volume of 78,978 shares, compared to its average volume of 1,519,480. Novo Nordisk A/S has a 12 month low of $43.60 and a 12 month high of $58.01. The stock has a market cap of $133.84 billion, a price-to-earnings ratio of 22.73, a P/E/G ratio of 2.26 and a beta of 0.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.73 and a current ratio of 1.00. The business has a 50-day simple moving average of $55.36 and a 200-day simple moving average of $51.57.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Friday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. The firm had revenue of $4.51 billion for the quarter, compared to analysts’ expectations of $4.55 billion. On average, equities research analysts forecast that Novo Nordisk A/S will post 2.44 EPS for the current year.

Large investors have recently added to or reduced their stakes in the stock. Cornerstone Advisors Inc. lifted its holdings in Novo Nordisk A/S by 5.0% in the second quarter. Cornerstone Advisors Inc. now owns 5,974 shares of the company’s stock valued at $305,000 after acquiring an additional 285 shares during the last quarter. AE Wealth Management LLC purchased a new position in Novo Nordisk A/S during the 2nd quarter valued at about $283,000. Cim LLC boosted its holdings in Novo Nordisk A/S by 2.0% during the 2nd quarter. Cim LLC now owns 196,089 shares of the company’s stock valued at $10,008,000 after acquiring an additional 3,861 shares during the period. Commerzbank Aktiengesellschaft FI boosted its holdings in Novo Nordisk A/S by 13.9% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 85,350 shares of the company’s stock valued at $4,356,000 after acquiring an additional 10,404 shares during the period. Finally, Arden Trust Co acquired a new position in Novo Nordisk A/S in the 2nd quarter valued at about $642,000. Hedge funds and other institutional investors own 7.32% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Read More: What is Cost of Capital?

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit